

**Eisai Co., Ltd.** 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan  
Phone: 03- 3817-5120 Fax: 03- 3811-3077

### 3. Transdermal Patch Formulation

Clinical trials of a once-a-week transdermal patch formulation of donepezil, which include a bioequivalence study compared to the currently marketed formulation of donepezil, are currently being conducted by Teikoku Pharma USA, Inc. in the United States. An NDA submission to the U.S. FDA is planned for the middle of fiscal year 2009 with the results of the clinical trials. Eisai is working on this new formulation of donepezil based on agreements with Teikoku Seiyaku Co., Ltd. and its U.S. subsidiary, Teikoku Pharma USA, Inc.

Contact: